Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > Immune Pharmaceuticals owns ICO 32 million dollars

<< Previous

Bullboard Posts

Next >>

Comment by allain250on Jun 22, 2018 8:15am

150 Views

Post# 28211201

RE:RE:RE:RE:Immune Pharmaceuticals owns ICO 32 million dollars

iCo-008: Completion of Ph 2 enrollment and report additional BP data Q2 2018*

Complete enrollment in Ph 2 UC study Q3 2018*

Aiming to launch pivotal BP study 2019*

Amphotericin B: Phase 1 clinical study enrollment completion (Australia) Q2 2018

Full data analysis Q3 2018

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing